嘉必優(688089.SH):擬購買歐易生物63.2134%的股權
格隆匯3月4日丨嘉必優(688089.SH)公佈,上市公司擬以發行股份及支付現金的方式向王樹偉、董棟、肖雲平、王修評、靳超、史賢俊、上海帆易、寧波睿歐、寧波歐潤、國藥二期、南通東證、蘇州鼎石、上海聖祁共13名交易對方購買歐易生物63.2134%的股權,並募集配套資金,交易價格83,062.37萬元。
本次交易前,上市公司以生物技術爲立足之本,以合成生物學爲底層技術,以細胞工廠爲製備方式,通過可持續的生物製造方式,爲全球營養與健康領域的客戶提供高品質的營養素產品與創新解決方案。在近二十年行業積累的基礎上,公司建立了完整的技術產業鏈轉化平臺,產品涵蓋花生四烯酸(ARA)、二十二碳六烯酸(DHA)、燕窩酸(SA)、β-胡蘿蔔素(BC)、母乳低聚糖(HMOs)等,廣泛應用於人類營養、動物營養、個護美妝等領域。標的公司以多組學技術與大數據分析技術爲基礎,主要提供以單細胞與時空組學爲特色的多組學技術服務,服務於生命科學基礎研究以及醫學、食品、營養、化妝品等領域應用研究,在行業內成功打造了“創新多組學”的優質品牌。
通過本次交易,上市公司與標的公司憑藉自身的業務與技術優勢,能夠爲彼此賦能和引流,形成技術研發、市場資源、戰略發展等多方面的協同效應。同時,藉助本次交易,上市公司將全面提升多組學與生物信息學底層技術能力,並將主營業務進一步向科研技術服務領域延伸,打造“技術服務+創新高價值分子挖掘+產品輸出”一體化的產業服務平臺,爲客戶提供完整解決方案。本次交易將助力雙方實現產品和服務的協同互補,有效強化上市公司技術研發實力和客戶服務能力,提升生產效率,補鏈強鏈,擴大公司整體規模,增強市場競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.